NCT00634205View on ClinicalTrials.gov

Phase II Study of Valproate and Doxorubicin in Malignant Mesothelioma

PHASE2CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

July 31, 2006

Primary Completion Date

March 31, 2009

Study Completion Date

June 30, 2010

Conditions
Malignant Mesothelioma
Interventions
DRUG

Valproate plus doxorubicin

Valproate 20-30 mg/kg orally (in order to obtain serum concentration between 50-100 mcg/ml) Doxorubicin 60 mg/m² intravenously every 3 weeks

Trial Locations (8)

1000

Department of Intensive Care Unit and Thoracic Oncology Institut Jules Bordet, Brussels

4800

CH Peltzer-La Tourelle, Verviers

6000

Department of Pneumology CHU Charleroi, Charleroi

6060

Department of Pneumology Hôpital Saint-Joseph, Gilly

7000

Hôpital Ambroise Paré, Mons

7360

Department of Pneumology CHR St joseph - Warquignies, Boussu

Unknown

Department of Pneumology Hôpital Ixelles-Molière, Brussels

Department of Pneumology CHRU Lille, Lille

All Listed Sponsors
lead

European Lung Cancer Working Party

OTHER

NCT00634205 - Phase II Study of Valproate and Doxorubicin in Malignant Mesothelioma | Biotech Hunter | Biotech Hunter